The Undruggable Yields

The protein is essentially smooth. No pockets, no grooves, nothing for a drug molecule to grab onto. In molecular biology, that's fortress architecture. Biochemists stared at KRAS the way climbers stare at a glass wall: theoretically a surface, practically nothing to grip. So they named it "undruggable" and moved on to more approachable targets, while pancreatic cancer remained one of the deadliest diagnoses in medicine — median survival hovering around six months.

Six months. Shorter than a film festival circuit.

KRAS is present in over 90% of pancreatic tumors. It functions as a cellular growth switch — normally it flips on, does its job, flips off. When mutated, the switch jams in the "on" position, commanding cells to multiply without limit. Targeting it directly was considered impossible. So researchers stopped trying to grab the knob and started dismantling the hinges.

Daraxonrasib doesn't target KRAS directly. It targets cyclophilin A — a molecular chaperone protein that assists KRAS during the folding process. By hijacking the helper, the drug reaches KRAS through a side door, binding to the active protein and interrupting its cancer-promoting signals. It's less "drug meets target" and more "drug stowaway hitches a ride on the protein janitor."

The Phase 3 trial results are hard to read without pausing. In 500 patients with metastatic pancreatic cancer, median survival went from 6.7 months to 13.2 months. Nearly doubled. Overall death risk reduced by 60%. In a cancer that has seen essentially no major therapeutic advances in decades, this is a different category of result — not incremental but structural.

The side effect profile is real: 86% of patients developed skin rash, plus mouth sores, diarrhea, and nausea. But notably, fewer patients discontinued treatment from severe side effects than from standard chemotherapy — a meaningful comparison in a disease where the cure often feels indistinguishable from the illness.

What matters most here isn't only the drug. It's the proof of concept. "Undruggable" was never a property of KRAS — it was a property of the approaches being tried. The protein was never impenetrable; it was approach-resistant. Daraxonrasib works by finding what the cancer depends on that it forgot to hide: the molecular machinery KRAS needs to function in the first place.

This is how science moves at its best. Not battering down walls. Noticing the door that was always there.

Forty years. One protein. One side door.

The undruggable yields.